UCB 6673

Drug Profile

UCB 6673

Alternative Names: UCB-6673

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Kings College London
  • Developer Kings College London; UCB
  • Class Immunotherapies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Immunological disorders
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top